Login
Register
RSS
News
PubMed
Corporate
Trials
Drugs
Careers
Channels
ReportsMerck, Takeda end Daxas deal
Merck & Co. Inc. (NYSE:MRK) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) mutually terminated a 2010 deal to co-promote Takeda's chronic obstructive pulmonary disease (COPD) drug Daxas roflumilast in France, Germany, Italy, Spain, Portugal and Cana..
Original Article: Merck, Takeda end Daxas deal
Channels 43 Associated Channels 
Pertussis Vaccine acellular Takeda
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the...
Rotavirus Vaccine Merck
Haemophilus b Vaccine Merck
Horse Serum Merck
Pneumococcal Vaccine Merck
Somatropin Hgh rDNA Merck Serono
Hepatitis B Vaccine rDNA Merck
Hepatitis A Virus Vaccine Merck
FSH rDNA Merck Serono
Associated Content for this Article
Latest Biotechnology, Pharmaceutical and Healthcare News
Searches Linking to this Page
takeda vaccine, takada merck agreemnt 2012 daxas , takada merck agreemnt 2012 daxas , merck and daxas end co-promotion, reimbursement daxas, daxas spain reimbursement, daxas spain reimbursement, reimbursement daxas, daxas/roflumilast reimbursement decision france, daxas france, daxas france, takeda rights to merck products, roflumilast reimbursment, daxas germany, daxas takeda merck
Twitter
Linkedin